Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

4BIO Capital

Investor type Venture Capital
Founders Andrey Kozlov Dmitry Kuzmin

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 12
Average round size
info
The average size of a deal this fund participated in
$33M
Portfolio companies 11
Rounds per year 1.50
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.08
Exits 5
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Life Science
  • Medical
  • Therapeutics
Summary

In 2014 was created 4BIO Capital, which is appeared as VC. The fund was located in Europe if to be more exact in United Kingdom. The main office of represented VC is situated in the London.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the 4BIO Capital, startups are often financed by Woodford Investment Management, Syncona Partners LLP, ODYSSEE VENTURE. The meaningful sponsors for the fund in investment in the same round are UCL Technology Fund, Temasek Holdings, RTW Investments LLC. In the next rounds fund is usually obtained by Auven Therapeutics, AstraZeneca, Redmile Group.

The fund is generally included in less than 2 deals every year. The higher amount of exits for fund were in 2018. This 4BIO Capital works on 51 percentage points more the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2017.

The fund has exact preference in some founders of portfolio startups. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Orchard Therapeutics, Atara Biotherapeutics, Cellectis. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom.

This organization was formed by Andrey Kozlov, Dmitry Kuzmin. We also calculated 3 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of 4BIO Capital:
Typical Co-investors
4BIO Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after 4BIO Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United Kingdom
Funds with similar focus located in United Kingdom:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Beazley Group England, London, United Kingdom
CMGE China, Hong Kong, Hong Kong Island
Creador Kuala Lumpur, Malaysia
Eastate Stockholm, Stockholm County, Sweden
Enlightened Capital -
Global eTrade Services (GeTS) Central, Central Region, Singapore
Haitao Capital China, Shanghai
iVentures Asia Ltd China, Hong Kong, Hong Kong Island
JLL Partners New York, New York, United States
MLS Players Association Bethesda, Maryland, United States
NantMobile California, Culver City, United States
Palladin Consumer Retail Partners Boston, Massachusetts, United States
PensionDanmark Copenhagen, Denmark, Hovedstaden
Rodman & Renshaw New York, New York, United States
Segittur Community of Madrid, Madrid, Spain
Shangshan Investment China, Shanghai
Simpact VC Mazowieckie, Poland, Warsaw
Strait Capital Investment Group China, Shanghai
Winton Ventures England, London, United Kingdom
ZL LLC Nashville, Tennessee, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Code Biotherapeutics

Biotechnology
Life Science
$75M07 Jun 2022 Hatfield, Pennsylvania, United States

LUCA Science

Biotechnology
Health Care
Pharmaceutical
$35M06 Jun 2022 Chiyoda, Japan

Ray Therapeutics

Biotechnology
Therapeutics
$6M04 Jan 2022 San Diego, California, United States

Code Biotherapeutics

Biotechnology
Life Science
$10M20 Apr 2021 Hatfield, Pennsylvania, United States

Araris Biotech

Biotechnology
$16M22 Oct 2020 Zurich, Zurich, Switzerland

SparingVision

Biotechnology
Life Science
$52M21 Oct 2020 Paris, Ile-de-France, France

Redpin Therapeutics

Biotechnology
Health Care
Pharmaceutical
$15M25 Mar 2020 New York, United States

Autolus

Biopharma
Biotechnology
Medical
Pharmaceutical
01 Jan 2018 England

Orchard Therapeutics

Biotechnology
Genetics
Health Care
Health Diagnostics
$110M20 Dec 2017 London, England, United Kingdom

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent 4BIO Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: